Yong Jiang Hei

机构：Amgen (United States)

发表论文 9 篇 · 总被引 765 次 · h-index 4

代表论文

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid (2005 · Journal of Clinical Oncology · 被引 533)
Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer (2006 · Clinical Cancer Research · 被引 154)
Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer (2007 · Urology · 被引 68)
Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC). (2012 · Journal of Clinical Oncology · 被引 4)
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. (2016 · Journal of Clinical Oncology · 被引 2)
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (2016 · Journal of Clinical Oncology · 被引 2)